MLN4924 was specifically designed as a first-in-class pharmacological inhibitor of NAE1 and has been investigated in various phase I–III clinical trials for leukemia, lymphoma, and advanced solid tumors [28]. This evidence concerns the gene NAE1 and lymphoma.